1. Home
  2. ALRS vs URGN Comparison

ALRS vs URGN Comparison

Compare ALRS & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALRS
  • URGN
  • Stock Information
  • Founded
  • ALRS 1879
  • URGN 2004
  • Country
  • ALRS United States
  • URGN United States
  • Employees
  • ALRS N/A
  • URGN N/A
  • Industry
  • ALRS Major Banks
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALRS Finance
  • URGN Health Care
  • Exchange
  • ALRS Nasdaq
  • URGN Nasdaq
  • Market Cap
  • ALRS 468.2M
  • URGN 463.2M
  • IPO Year
  • ALRS 2019
  • URGN 2017
  • Fundamental
  • Price
  • ALRS $21.01
  • URGN $4.24
  • Analyst Decision
  • ALRS Hold
  • URGN Strong Buy
  • Analyst Count
  • ALRS 5
  • URGN 8
  • Target Price
  • ALRS $23.20
  • URGN $27.92
  • AVG Volume (30 Days)
  • ALRS 88.0K
  • URGN 2.4M
  • Earning Date
  • ALRS 07-23-2025
  • URGN 05-12-2025
  • Dividend Yield
  • ALRS 3.99%
  • URGN N/A
  • EPS Growth
  • ALRS 118.02
  • URGN N/A
  • EPS
  • ALRS 1.08
  • URGN N/A
  • Revenue
  • ALRS $224,218,000.00
  • URGN $91,871,000.00
  • Revenue This Year
  • ALRS $40.50
  • URGN $35.06
  • Revenue Next Year
  • ALRS $3.54
  • URGN $112.94
  • P/E Ratio
  • ALRS $19.39
  • URGN N/A
  • Revenue Growth
  • ALRS 35.73
  • URGN 8.98
  • 52 Week Low
  • ALRS $15.78
  • URGN $3.42
  • 52 Week High
  • ALRS $24.41
  • URGN $20.70
  • Technical
  • Relative Strength Index (RSI)
  • ALRS 55.57
  • URGN 27.72
  • Support Level
  • ALRS $20.83
  • URGN $3.71
  • Resistance Level
  • ALRS $21.75
  • URGN $4.25
  • Average True Range (ATR)
  • ALRS 0.58
  • URGN 0.91
  • MACD
  • ALRS -0.21
  • URGN -0.45
  • Stochastic Oscillator
  • ALRS 23.23
  • URGN 9.87

About ALRS Alerus Financial Corporation

Alerus Financial Corp is a financial holding company registered in the United States. The company operates in four segments: Banking, Retirement & Benefit Services, Wealth Management, and Mortgage. It provides various banking services such as checking, debit cards, savings, current deposits, loans and advances, online banking, mobile banking, private banking, payment solutions, and other business products. Additionally, the company provides mortgage loans, retirement planning solutions, individual retirement accounts, retirement plan advisory services as well as wealth management services, including financial & estate planning, trust, and fiduciary services. The company's revenue mainly consists of interest income, commission, management fees, and other income.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: